Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Radiation monitoring

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    111 result(s) found for: Radiation monitoring. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2018-004490-27 Sponsor Protocol Number: 18POUM06 Start Date*: 2019-09-11
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001709-25 Sponsor Protocol Number: CCR5119 Start Date*: 2020-02-06
    Sponsor Name:The Institute of Cancer Research
    Full Title: Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer
    Medical condition: Patients with locally advanced/recurrent breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003680-25 Sponsor Protocol Number: CNAO_44-2021C_ICONIC Start Date*: 2021-12-14
    Sponsor Name:Fondazione CNAO Centro Nazionale di Adroterapia Oncologica
    Full Title: Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
    Medical condition: • Unresectable or metastatic melanoma • Locally advanced or metastatic non-small cell lung cancer (NSCLC) • Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSC...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027467 Metastases to specified sites HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006421-13 Sponsor Protocol Number: BBD Start Date*: 2008-11-28
    Sponsor Name:Wilhelminen Krebsforschung GmbH
    Full Title: Multicenter Phase II Study: Bendamustine plus Bortezomib plus Dexamethasone in the treatment of stage II/III relapsed or refractory multiple myeloma
    Medical condition: Patients suffering from stage II/III (Salmon & Durie) relapsed or refractory multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000864-42 Sponsor Protocol Number: IFX-1-P2.8 Start Date*: 2021-04-27
    Sponsor Name:InflaRx GmbH
    Full Title: OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOU...
    Medical condition: Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003582-28 Sponsor Protocol Number: LOXO-TRK-15002 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) IE (Completed) ES (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) BE (Completed) CZ (Completed) SK (Completed) NO (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002066-24 Sponsor Protocol Number: PrE0204 Start Date*: 2015-08-28
    Sponsor Name:The All Ireland Cooperative Oncology Research Group (ICORG)
    Full Title: A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma
    Medical condition: Advanced or metastatic cholangiocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002054-39 Sponsor Protocol Number: ODX-002 Start Date*: 2014-11-10
    Sponsor Name:DexTech Medical AB
    Full Title: A randomized, double-blind, placebo-controlled multi-centre phase II study to evaluate efficacy and tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
    Medical condition: Metastatic Castration Resistant Prostate Cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004053-88 Sponsor Protocol Number: EuroNet-PHL-C2 Start Date*: 2015-07-01
    Sponsor Name:Justus-Liebig-University Giessen
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: Hodgkin lymphoma in children and adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) NL (Completed) DK (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021070-11 Sponsor Protocol Number: 005/05E Start Date*: 2010-11-23
    Sponsor Name:BioVex Inc
    Full Title: An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEX GM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
    Medical condition: Unresectable Stage IIIb, IIIc and IV Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012934-63 Sponsor Protocol Number: D0102C00004 Start Date*: 2009-10-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-men...
    Medical condition: Locally Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005666-37 Sponsor Protocol Number: ODX-003 Start Date*: 2016-02-26
    Sponsor Name:DexTech Medical AB
    Full Title: A randomized, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases
    Medical condition: Metastatic Castration Resistant Prostate Cancer (CRPC) and skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) EE (Completed) LV (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000951-14 Sponsor Protocol Number: RhoVac-002 Start Date*: 2019-08-26
    Sponsor Name:RhoVac ApS
    Full Title: A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed) FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-001436-10 Sponsor Protocol Number: INCB18424-266 Start Date*: 2015-02-26
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small C...
    Medical condition: Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004501-24 Sponsor Protocol Number: CT-2011-01 Start Date*: 2012-03-06
    Sponsor Name:CureTech Ltd.
    Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000232-34 Sponsor Protocol Number: NASIR-HCC Start Date*: 2017-09-11
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment o...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-005251-25 Sponsor Protocol Number: CABACARE Start Date*: 2017-04-07
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, p...
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003836-22 Sponsor Protocol Number: 114-NH-301 Start Date*: 2007-03-15
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory,...
    Medical condition: Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029627 Non-Hodgkin's lymphoma unspecified histology intermediate grade refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) LT (Prematurely Ended) GB (Completed) SE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) LV (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021946-22 Sponsor Protocol Number: DeCOG–MM-PAL11 Start Date*: 2011-04-05
    Sponsor Name:University Hospital Essen
    Full Title: THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA: PROSPECTIVE CLINICAL PHASE II MULTIBASKET STUDY IN OCULAR MELANOMA PATIENTS WITH ADVANCED DISEASE
    Medical condition: Histologically proven uveal melanoma Measurable disease according to RECIST in unresectable stage III-IV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068117 Metastatic ocular melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000618-23 Sponsor Protocol Number: ORN-01 Start Date*: 2015-05-05
    Sponsor Name:Västra Götalandsregionen/NÄL
    Full Title: Treatment of osteoradionecrosis (ORN) with pentoxifylline and α-tocopherol (PENTO)
    Medical condition: Osteoradionecrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10031264 Osteonecrosis PT
    18.0 10022117 - Injury, poisoning and procedural complications 10067352 Osteoradionecrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:17:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA